In this work, the scientists contrast the use of these genome editing tools in two myopathies with very different molecular origins: Duchenne muscular dystrophy, a monogenetic disease, and facioscapulohumeral muscular dystrophy, an epigenetic disorder with unique therapeutic challenges.
In this study, the authors present here the CRISPR-induced deletion (CinDel), a new promising genome-editing technology to correct the DMDgene. Using an adequate pair of gRNAs, the deletion of parts of these exons and the intron separating them restored the DMDreading frame in 62% of the hybrid exons in vitro in DMD myoblasts and in vivo in electroporated hDMD/mdx mice. Given that CinDel induces permanent reparation of the DMDgene, this treatment would not have to be repeated as it is the case for exon skipping induced by oligonucleotides.
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
In this work, the scientists contrast the use of these genome editing tools in two myopathies with very different molecular origins: Duchenne muscular dystrophy, a monogenetic disease, and facioscapulohumeral muscular dystrophy, an epigenetic disorder with unique therapeutic challenges.